Study Reveals Potential Anti-Aging Effects and Safety of NMN Supplement
Introduction: Advancements in medical sciences have increased human lifespan, leading to a burden on governmental finances. To address this, scientists are exploring anti-aging compounds, including pharmaceutical drugs. One such compound is Nicotinamide mononucleotide (NMN), which plays a role in cellular processes and NAD+ biosynthesis. NAD+ deficiency is associated with aging and age-related diseases. NMN has been evaluated in human subjects and found to be safe for use, leading to its current evaluation in clinical trials for its effects on various conditions and as an anti-aging supplement.
Study Design and Population:
A double-blind, parallel, randomized controlled clinical trial was conducted in Pune, India. The study included 66 healthy subjects aged 40-65 years. Subjects were instructed to take two capsules of NMN or placebo once a day for 60 days. The study population had similar demographics and baseline characteristics between the treatment groups.
The study found that NMN supplementation resulted in a significant increase in NAD+/NADH levels in the serum compared to the placebo group at day 30 and day 60. This suggests the potential of NMN to increase energy levels and have an anti-aging effect. The NMN group also showed a higher increase in SF-36 scores, indicating improved well-being, compared to the placebo group at day 60. Additionally, the NMN group displayed no significant change in the HOMA IR Index, a parameter for checking insulin sensitivity, while there was a significant increase in the placebo group at the end of the study.
Safety and Conclusion:
NMN supplementation was found to be safe for use, with no clinically meaningful derangement in safety laboratory tests and no significant adverse events. There were no statistically significant differences in blood pressure, lipid profile, liver function, kidney function, and electrolyte levels between the active and placebo groups. The study suggests the potential applications of NMN in aging reversal, organ regeneration, metabolic disorders, and cancer prevention. Larger-scale trials with increased dose and duration of treatment are needed to establish definitive conclusions.
Clinical Trials and Conflict of Interest:
The study was registered on clinicaltrials.gov with the identifier NCT04228640. Several other clinical trials related to NMN were also identified. The data supporting the conclusions of the study will be made available by the authors. It is important to note that one of the authors was employed by Effepharm (Shanghai) Co., Ltd., which could potentially influence objectivity or bias.
The claims expressed in the article are the opinions of the authors and may not represent the opinions of their affiliated organizations, the publisher, the editors, or the reviewers. Additionally, the endorsement or guarantee of any product or manufacturer's claims mentioned in the article is not provided by the publisher.
Title of paper: A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults
Author(s): Huang H.
Year published: 2022
Published in: Front Aging
Original article can be found here."